{"article_title": "Johnson & Johnson Earnings: Showing Surprising Weakness -- The Motley Fool", "article_keywords": ["fool", "surprising", "johnson", "weedbut", "motley", "weakness", "showing", "revenue", "surface", "video", "earnings", "yearoveryear", "things", "solidly", "thinks", "stock"], "article_url": "http://www.fool.com/investing/general/2014/10/15/johnson-johnson-earnings-showing-surprising-weakne.aspx", "article_text": "Johnson & Johnson (NYSE:JNJ) had what on the surface appeared to be a pretty good quarter -- revenue and earnings were up solidly year-over-year, and the pharma business grew like a weed.\n\nBut looking under the surface, things didn't appear nearly as positive. And in the video below, Motley Fool health care analyst Michael Douglass lays out his concerns with Johnson & Johnson and what he thinks about this top dividend stock.", "article_metadata": {"publish_time": "13:46", "promo": "Johnson & Johnson's strong earnings masked some surprising weaknesses. Watch below to find out more.", "description": "Johnson & Johnson's strong earnings masked some surprising weaknesses. Watch below to find out more.", "ResponsiveALP": "1Ses_2things-v-single_single-control_50", "author": "Michael Douglass and Alison Southwick", "headline": "Johnson & Johnson Earnings: Showing Surprising Weakness", "twitter": {"title": "Johnson & Johnson Earnings: Showing Surprising Weakness --  The Motley Fool", "description": "Johnson & Johnson's strong earnings masked some surprising weaknesses. Watch below to find out more.", "site": "@themotleyfool"}, "og": {"site_name": "The Motley Fool", "description": "Johnson & Johnson's strong earnings masked some surprising weaknesses. Watch below to find out more.", "title": "Johnson & Johnson Earnings: Showing Surprising Weakness --  The Motley Fool", "url": "http://www.fool.com/investing/general/2014/10/15/johnson-johnson-earnings-showing-surprising-weakne.aspx", "image": "https://g.foolcdn.com/image/?url=http%3A%2F%2Fg.foolcdn.com%2Fassets%2Fimages%2Ffool%2Ftmf-logo.png&h=630&w=1200&op=resize", "type": "article"}, "fb": {"admins": 50808187550, "page_id": 7240312795, "app_id": 50808187550}, "bureau": "usmf-health-care", "STORY_UID": "002f832a-5493-11e4-a00d-0050569d32b9", "pitch": 823, "msvalidate.01": "8D40D58712924715BAA79D135A6C8DDA", "gsa_date": "2014 10 15", "tickers": "JNJ,SHPG,ABBV", "date": "2014-10-15T17:46:00Z", "viewport": "width=device-width, initial-scale=1.0, maximum-scale=1.0"}, "article_summary": "And in the video below, Motley Fool health care analyst Michael Douglass lays out his concerns with Johnson & Johnson and what he thinks about this top dividend stock.\nJohnson & Johnson (NYSE:JNJ) had what on the surface appeared to be a pretty good quarter -- revenue and earnings were up solidly year-over-year, and the pharma business grew like a weed.\nBut looking under the surface, things didn't appear nearly as positive."}